Repositorio Dspace

Suboptimal monitoring and management in patients with unrecorded stage 3 chronic kidney disease in real-world settings: Insights from REVEAL-CKD

Mostrar el registro sencillo del ítem

dc.contributor.author Tangri, Navdeep
dc.contributor.author Álvarez, Christian-S
dc.contributor.author Arnold, Matthew
dc.contributor.author Barone, Salvatore
dc.contributor.author Cebrián, Ana
dc.contributor.author Chen, Hungta
dc.contributor.author de-Nicola, Luca
dc.contributor.author Jarbrink, Krister
dc.contributor.author Kanumilli, Naresh
dc.contributor.author Lim, Kean-Seng
dc.contributor.author Moriyama, Toshiki
dc.contributor.author Pecoits-Filho, Roberto
dc.contributor.author Ribeiro-de-Castro, María-Cristina
dc.contributor.author Santamaria, Rafael
dc.contributor.author Schneider, Markus-P
dc.contributor.author Virgitti, Jean-Blaise
dc.contributor.author Kushner, Pamela
dc.date.accessioned 2025-11-20T07:25:36Z
dc.date.available 2025-11-20T07:25:36Z
dc.date.issued 2024-11
dc.identifier.citation Tangri N, Alvarez CS, Arnold M, Barone S, Cebrián A, Chen H, et al. Suboptimal monitoring and management in patients with unrecorded stage 3 chronic kidney disease in real-world settings: Insights from REVEAL - CKD. Eur J Clin Investigation. noviembre de 2024;54(11):e14282.
dc.identifier.issn 0014-2972
dc.identifier.uri https://sms.carm.es/ricsmur/handle/123456789/21594
dc.description.abstract BACKGROUND: Clinical practice guidelines for patients with chronic kidney disease (CKD) recommend regular monitoring and management of kidney function and CKD risk factors. However, the majority of patients with stage 3 CKD lack a diagnosis code, and data on the implementation of these recommendations in the real world are limited. AIM: To assess the implementation of guideline-directed monitoring and management practices in the real world in patients with stage 3 CKD without a recorded diagnosis code. METHODS: REVEAL-CKD (NCT04847531) is a multinational, observational study of patients with stage 3 CKD. Eligible patients had ?2 consecutive estimated glomerular filtration rate (eGFR) measurements indicative of stage 3 CKD recorded >90 and ?730 days apart, lacked an International Classification of Diseases 9/10 diagnosis code corresponding to CKD any time before and up to 6 months after the second eGFR measurement. Testing of key measures of care quality were assessed. RESULTS: The study included 435,971 patients from 9 countries. In all countries, the prevalence of urinary albumin-creatinine ratio and albuminuria testing was low. Angiotensin-converting enzyme inhibitor, angiotensin receptor blocker and statin prescriptions were highly variable, and sodium-glucose cotransporter-2 inhibitor prescriptions remained below 21%. Blood pressure measurements were recorded in 20.2%-89.9% of patients. CONCLUSIONS: Overall, a large proportion of patients with evidence of stage 3 CKD did not receive recommended, guideline-directed monitoring and management. The variability in standard of care among countries demonstrates a clear opportunity to improve monitoring and management of these patients, most likely improving long-term outcomes.
dc.language.iso eng
dc.publisher WILEY
dc.rights http://creativecommons.org/licenses/by-nc-nd/3.0/es/
dc.rights.uri Atribución-NoComercial-SinDerivadas 3.0 España *
dc.subject.mesh Humans
dc.subject.mesh Male
dc.subject.mesh Female
dc.subject.mesh Glomerular Filtration Rate
dc.subject.mesh Renal Insufficiency, Chronic/physiopathology
dc.subject.mesh Aged
dc.subject.mesh Middle Aged
dc.subject.mesh Angiotensin-Converting Enzyme Inhibitors/therapeutic use
dc.subject.mesh Angiotensin Receptor Antagonists/therapeutic use
dc.subject.mesh Albuminuria
dc.subject.mesh Hydroxymethylglutaryl-CoA Reductase Inhibitors/therapeutic use
dc.subject.mesh Guideline Adherence
dc.subject.mesh Sodium-Glucose Transporter 2 Inhibitors/therapeutic use
dc.subject.mesh Creatinine
dc.subject.mesh Blood Pressure/physiology
dc.subject.mesh Practice Guidelines as Topic
dc.title Suboptimal monitoring and management in patients with unrecorded stage 3 chronic kidney disease in real-world settings: Insights from REVEAL-CKD
dc.type info:eu-repo/semantics/article
dc.identifier.pmid 39023418
dc.relation.publisherversion https://onlinelibrary.wiley.com/doi/10.1111/eci.14282
dc.identifier.doi 10.1111/eci.14282
dc.journal.title European Journal of Clinical Investigation
dc.identifier.essn 1365-2362


Ficheros en el ítem

Este ítem aparece en la(s) siguiente(s) colección(ones)

Mostrar el registro sencillo del ítem

Buscar en DSpace


Búsqueda avanzada

Listar

Mi cuenta